These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 31502694)

  • 21. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
    Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology.
    Neely M; Bayard D; Desai A; Kovanda L; Edginton A
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S73-S85. PubMed ID: 30248199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson TN; Ke AB
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.
    Yellepeddi V; Rower J; Liu X; Kumar S; Rashid J; Sherwin CMT
    Clin Pharmacokinet; 2019 Jan; 58(1):1-13. PubMed ID: 29777528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.
    Cheung KWK; van Groen BD; Burckart GJ; Zhang L; de Wildt SN; Huang SM
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S56-S69. PubMed ID: 31502692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.
    Wang K; Jiang K; Wei X; Li Y; Wang T; Song Y
    AAPS PharmSciTech; 2021 Jul; 22(6):208. PubMed ID: 34312742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.
    Zhao P; Rowland M; Huang SM
    Clin Pharmacol Ther; 2012 Jul; 92(1):17-20. PubMed ID: 22713733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips.
    Prantil-Baun R; Novak R; Das D; Somayaji MR; Przekwas A; Ingber DE
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():37-64. PubMed ID: 29309256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
    Rioux N; Waters NJ
    Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
    Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
    Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019.
    Khong YM; Liu J; Cook J; Purohit V; Thompson K; Mehrotra S; Cheung SYA; Hay JL; Fletcher EP; Wang J; Sachs HC; Zhu H; Siddiqui A; Cunningham L; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():66-74. PubMed ID: 33878434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute.
    Smits A; De Cock P; Vermeulen A; Allegaert K
    Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):25-34. PubMed ID: 30554542
    [No Abstract]   [Full Text] [Related]  

  • 34. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 36. The utility of modeling and simulation in drug development and regulatory review.
    Huang SM; Abernethy DR; Wang Y; Zhao P; Zineh I
    J Pharm Sci; 2013 Sep; 102(9):2912-23. PubMed ID: 23712632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental Pharmacodynamics and Modeling in Pediatric Drug Development.
    Conklin LS; Hoffman EP; van den Anker J
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S87-S94. PubMed ID: 31502687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.
    Wang J; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.